Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVA8R9
|
|||
| Drug Name |
Olezarsen
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Familial chylomicronemia syndrome [ICD-11: 5C80; ICD-10: J10, J11] | Phase 3 | [1] | |
| Hypertriglyceridemia [ICD-11: 5C80.1; ICD-10: E78.1, E78.3; ICD-9: 272.1, 427] | Phase 3 | [2] | ||
| Company |
Ionis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ApoC-III messenger RNA (APOC3 mRNA) | Target Info | Inhibitor | [3] |
| KEGG Pathway | PPAR signaling pathway | |||
| Reactome | Chylomicron-mediated lipid transport | |||
| HDL-mediated lipid transport | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Statin Pathway | |||
| PPAR Alpha Pathway | ||||
| Visual phototransduction | ||||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05130450) An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05681351) An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). U.S.National Institutes of Health. | |||
| REF 3 | Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022 Apr 6;43(14):1401-1412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.